Patents Assigned to GlaxoSmithKline
-
Patent number: 11945826Abstract: The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof.Type: GrantFiled: February 11, 2020Date of Patent: April 2, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Mark Elban, Michal Pawel Glogowski, Michael Clinton Koetting, Brian Griffin Lawhorn, Jay M. Matthews, Jaclyn Renee Patterson
-
Patent number: 11944675Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.Type: GrantFiled: October 2, 2020Date of Patent: April 2, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Fabiana Fernandez, Michael Kowarik, Michael Wacker, Michael Wetter
-
Publication number: 20240100140Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.Type: ApplicationFiled: April 6, 2023Publication date: March 28, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Amirreza FARIDMOAYER, Rainer FOLLADOR, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Gerd Martin LIPOWSKY, Gerald Johann POSCH, Fabio SERVENTI
-
Patent number: 11939357Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHpb which can be modified to enhance their properties.Type: GrantFiled: June 14, 2021Date of Patent: March 26, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Matthew Bottomley, Vega Masignani
-
Publication number: 20240093161Abstract: A simian adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein the first expression cassette is inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is inserted in a region of the adenoviral vector that is compatible with vector replication.Type: ApplicationFiled: August 21, 2023Publication date: March 21, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Stefano COLLOCA
-
Publication number: 20240091338Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.Type: ApplicationFiled: February 28, 2023Publication date: March 21, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alfredo Nicosia, Ricardo Cortese, Alessandra Vitelli
-
Publication number: 20240091345Abstract: The present invention relates to a nucleic acid encoding a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a nucleic acid encoding a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.Type: ApplicationFiled: January 18, 2022Publication date: March 21, 2024Applicant: GlaxoSmithKline Biologicals SAInventors: Johann MOLS, Marie TOUSSAINT
-
Patent number: 11932671Abstract: Modified meningococcal fHbp polypeptides with increased stability.Type: GrantFiled: April 30, 2021Date of Patent: March 19, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Matthew Bottomley, Enrico Malito, Manuele Martinelli, Maria Scarselli
-
Patent number: 11932669Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.Type: GrantFiled: April 6, 2021Date of Patent: March 19, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Enrico Malito, Matthew James Bottomley, Andrea Carfi, Sumana Chandramouli, Kate Luisi
-
Patent number: 11931405Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: July 28, 2022Date of Patent: March 19, 2024Assignees: GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Publication number: 20240083896Abstract: Compounds of formula (I) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (I), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions, such as atrial fibrillation.Type: ApplicationFiled: December 16, 2021Publication date: March 14, 2024Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Xiaoyang DONG, Mark Andrew ELBAN, Jie GUANG, Ming-Hsun HO, Tram H. HOANG, Joseph J. ROMANO, David Glenn WASHBURN
-
Publication number: 20240082329Abstract: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigens in two different forms—a first antigen from a pathogen, in RNA-coded form; and a second antigen from a different pathogen, in polypeptide form—are effective in inducing immune response to both pathogens.Type: ApplicationFiled: September 7, 2023Publication date: March 14, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew GEALL, Ethan SETTEMBRE
-
Publication number: 20240076318Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.Type: ApplicationFiled: July 25, 2023Publication date: March 7, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefania CAPONE, Antonella FOLGORI, Armin LAHM, Benjamin WIZEL
-
Publication number: 20240075125Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.Type: ApplicationFiled: May 22, 2023Publication date: March 7, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
-
Patent number: 11918643Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.Type: GrantFiled: December 21, 2021Date of Patent: March 5, 2024Assignees: CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
-
Patent number: 11913001Abstract: Provided is RNA encoding an immunogen is delivered to a large mammal at a dose of from 5 ?g to 100 ?g or at a dose between 0.1 ?g per kilogram body mass of the large mammal and 1.5 ?g per kilogram body mass of the large mammal. Provided is a method of raising an immune response in a large mammal, comprising administering to the large mammal a dose of from 5 ?g to 100 ?g or a dose of between 0.1 ?g of RNA encoding the immunogen per kilogram body mass of the large mammal and 1.5 ?g of RNA encoding the immunogen per kilogram body mass of the large mammal. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: October 27, 2021Date of Patent: February 27, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall
-
Patent number: 11905514Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: February 20, 2024Assignee: GLAXOSMITHKLINE BIOLOGICAL SAInventor: Andrew Geall
-
Publication number: 20240051972Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.Type: ApplicationFiled: August 31, 2022Publication date: February 15, 2024Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare CompanyInventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
-
Patent number: 11896636Abstract: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigens in two different forms—a first antigen from a pathogen, in RNA-coded form; and a second antigen from a different pathogen, in polypeptide form—are effective in inducing immune response to both pathogens.Type: GrantFiled: July 6, 2012Date of Patent: February 13, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew Geall, Ethan Settembre
-
Patent number: 11891608Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.Type: GrantFiled: December 13, 2022Date of Patent: February 6, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Andrew Geall